Buy compass pathways stock. 84 (25 minute delay). COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy? 09/08/23-8:55AM EST Zacks Pediatrix (MD) Down 4. The company's fresh look at psychedelic drugs is attracting lots of attention. (0. Morgan Stanley began coverage […] Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Analyst Sumant Aug 25, 2022 · What happened. Progress continues on the company's work to develop a mental These investments are made available by existing Compass Pathways shareholders who sell their shares on our platform. 63%) rose by a noteworthy 15. ET. Nov 4, 2020 · Compass Pathways Stock Shares closed off session highs but still jumped 8. We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. 00 ,the lowest forecast is $22. 2/23/2024. Rating: Sentiment May 15, 2024 · COMPASS Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. 6 days ago · The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by HC Wainwright & Co. Notes & Data Providers. The average target predicts an increase of 512. Compass Pathways Plc ADR (NASDAQ: CMPS) has experienced a decline in its stock price by -13. 81M. Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis. 00M. CMPS Competitors. 00 target price on the stock. $10. 27%) $0. News releases. This was below the analyst estimate for EPS of -49 May 8, 2024 · Balance Sheet. Jason McCarthy’s Buy rat May 13, 2024 · COMPASS continues to maintain a strong financial position with cash and cash equivalents of $262. View real-time CMPS stock price and news, along with industry-best analysis. May 8, 2024 · Compass Pathways (NASDAQ: CMPS) just reported results for the first quarter of 2024. → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) Free CMPS Stock Alerts. Compass Pathways PLC (ADR) does not currently pay a dividend. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom. 8% through the first four days of trading this week, according to data from S&P May 15, 2024 · In other COMPASS Pathways news, Director George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock in a transaction on Tuesday, March 12th. 33. The analyst firm set a price target for 120. Shares of Compass Pathways ( CMPS -7. 16. 28. InvestorPlace reported 2024-01-09 that Though psychedelic therapies and related psychedelic stocks have Average. X. +$0. 39 entry. Shares surged 70. 30%, to $-90. The latest price was $7. During the last trading day the stock fluctuated 2. 74%) Buy COMPASS Pathways Shares. Price as of May 20, 2024, 4:00 p. $40. 16 (+1. co/fees for details. income statement | balance sheet | cash flow. Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to Jan 13, 2023 · COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). 92. 6% to close at 29. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). -2. The latest COMPASS Pathways stock prices, stock quotes, news, and CMPS history to help you invest and trade smarter. 18%. m. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Research & Ratings. Getting Started. InvestorsObserver’s proprietary ranking system, gives CMPS stock a score of 85 out of a possible 100. Our annual review. Cash & Cash Equivalents. 45 to a day high of $7. 99. Typically, these are early employees who need to fund a life event – house, education, etc. 44. 76%) and Jazz Pharmaceuticals ( JAZZ -0. 04M to $-123. Today's Change. Wainwright, reiterated the Buy rating on COMPASS Pathways (CMPS – Research Report). The company has $263. 02% upside from current levels. COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head Mar 18, 2024 · COMPASS Pathways (CMPS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. 8% upside potential Nov 9, 2021 · What happened. 53, for a total value of $203,704. 57%. Step 1: Choose a broker. The highest analyst price target is $120. 06 on Monday, opened at $40. Mar 5, 2024 · Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of $22. 27%) saw its shares drop more than 22% on Tuesday. CMPS Aug 4, 2023 · The word on The Street in general, suggests a Strong Buy analyst consensus rating for COMPASS Pathways with a $48. 230. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Mar 1, 2024 · Patrick Trucchio, an analyst from H. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The stock was sold at an average price of $8. -3. The company's market cap of $1. 09% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. May 22, 2024 · COMPASS Pathways EBITDA Forecast for 2023 - 2025 - 2030. Price as of May 24, 2024, 4:00 p. Aug 16, 2023 · Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 American Depositary Oct 12, 2022 · First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 . 22. FA Corner Compass Pathways jumped in its first day of trading on Friday, making it the first psychedelic drug company to go public on a big U. 17. FROG JFrog Ltd. 8. Feb 1, 2024 · To see InvestorsObserver's Sentiment Score for Compass Pathways PLC click here. Market Cap. 86. 6 days ago · Compass Pathways PLC (ADR)’s trailing 12-month revenue is $0. Other Robinhood Financial fees may apply, check rbnhd. The last 3 analyst ratings were released from HC Wainwright & Co. 68). 70% from the current stock price of 7. COMPASS Pathways is listed on the NASDAQ and traded in US dollars. Nov 12, 2021 · Shares of the psychedelic healthcare company Compass Pathways ( CMPS 3. Sep 7, 2023 · Follow these four steps to buy Compass Pathways stock: Select an online broker; Register with your chosen broker and deposit funds to your account; Buy CMPS stock; Periodically monitor your position in the company and adjust your holdings accordingly. -0. 01 after a previous close of $7. 72. 166. 28M. Wainwright, reiterated the Buy rating on COMPASS Pathways (CMPS – Research Report). The share price is up +165% in four months compared to a Nasdaq return of +22% over the same time frame. Jan 7, 2024 · BTIG analyst Thomas Shrader maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) on January 5 and set a price target of $3 May 21, 2024 · The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Compass Pathways Plc wasn’t one of them. $511M. That was the day Compass Pathways had their IPO, and today shares are trading at around $45 a share. 11,862. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving Nov 3, 2023 · Maxim Group analyst Jason McCarthy has maintained their bullish stance on CMPS stock, giving a Buy rating today. 61%) Updated May 29, 2024 12:04 PM ET. 33 is 12. 32. Compass Pathways is listed on the NASDAQ and employs 186 staff. That's an unattractive 6 days ago · The Compass Pathways PLC stock price gained 0. S. Market open. 11 (+1. 58, established from looking at the 32 latest analyst ratings. In the last three years, COMPASS Pathways's EBITDA has grown, increasing from $-47. 00 expecting CMPS to rise to At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. , Cantor May 13, 2022 · The company has a Strong Buy consensus rating based on four Buys, zero Holds, and zero Sell ratings. The 10 stocks that May 21, 2024 · Berenberg Resumes COMPASS Pathways at Buy With $33 Price Target 22-11-21: MT COMPASS Pathways Stock Rises After Oppenheimer Initiates Coverage 6 days ago · Get Insider Trades Delivered To Your Inbox. They currently have a $120. Sell. The average price target for COMPASS Pathways is $45. 93% in its stock price over the last five trading days. SEC filings & annual reports. 2 million. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and May 22, 2024 · The Price to Sales ratio or P/S is calculated as price divided by sales. 39. 40 and closed Feb 8, 2024 · Compass Pathways plc, a biotech firm, faces hurdles in its development of a psilocybin-based therapy for CNS disorders. Shares of the mental healthcare company Compass Pathways ( CMPS -0. . 24. Compass Pathways Plc (CMPS) is a publicly traded medical care facilities business based in the US which employs around 200 staff. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health Dec 7, 2023 · About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. 0 million with a % profit margin. 28 million in cash and $32. 2% Despite Q1 Earnings & Revenue Beat 05/05/23-11:16AM EST Zacks Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights. Whereas Jazz has a market cap of $8. 5 days ago · COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) major shareholder George Jay Goldsmith sold 23,881 shares of the firm's stock in a transaction dated Tuesday, April 16th. Ekaterina Malievskaia. The biotech stock, which focuses on mental health treatment, closed at $43. Add to portfolio. The associated price target is $120. Research COMPASS Pathways' (Nasdaq:CMPS) stock price, latest news & stock analysis. After the P/E ratio, it's one of the most common valuation metrics. The price has been going up and down for this period, and there has been a -4. 00 in the Compass Pathways PLC has a consensus price target of $42. Options. Related Tickers. Year-over-year quarterly sales growth most recently was %. $8. C. News & events. type (sell/buy) option Malievskaia Ekaterina: 05/02/2024 18,762. $119,331. 48. 93. Find everything from its Valuation, Future Growth, Past Performance and more. Assuming Top Stocks to Buy in ##YEAR## Stock Market News Retirement. 17 average price target, implying a 427. 15%. BE) Berlin - Berlin Delayed price. COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head Feb 19, 2024 · CMPS. Compass Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock. Compass Pathways stock is in an IPO base with a 47. 268% on the last trading day (Friday, 24th May 2024), rising from $7. . Compass Pathways ( CMPS 0. 47 million or $3. 176,100. Mar 5, 2024 · Compass Pathways PLC stock is higher by 42. Psychedelic medicines are rapidly gaining legitimacy on several fronts. Find the latest COMPASS Pathways plc (CMPS) stock quote, history, news and other vital information to help you with your stock trading and investing. Retirement 101 6 days ago · Stock Price Forecast. It opened the day at $8. StockGrader. Following the completion of the transaction, the insider now owns 3,986,523 shares in Oct 12, 2022 · Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression Apr 10, 2023 · Looking at the chart below, a reader unfamiliar with UK-based and Nasdaq-listed COMPASS Pathways plc (NASDAQ:CMPS) would most probably assume that things have gone pretty terribly for the company Complete COMPASS Pathways PLC ADR stock information by Barron's. Net Cash. If the P/S ratio is 1, that means you're paying $1 for Mar 1, 2024 · Additionally, Kulkarni maintains his $50 price target for COMPASS Pathways, underlined by the unchanged timeline for the COMP006 Phase 3 trial and the expected filing of a New Drug Application. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued. 75. Find the latest Compass Pathways PLC (5Y6. 46 to $7. Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has completed psilocybin administration to the target 216 patients in its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant You can buy and sell Compass Pathways (CMPS) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Click Here to get the full Stock Report for Compass Pathways PLC Shares jumped 71% to $29 in New York after an initial public offering of 7. 5 million shares priced at $17 each. CMPS has an average analyst ranking of Strong Buy with an average price target of $48. 02. 37 per share. $ Market cap P/E ratio $ Price 1d change 52-week range. Current Price. 12 (-1. Events. A number of other equities analysts have also recently issued reports on the company. The stock is trading up 19. 6 days ago · See which brokers are best for buying COMPASS Pathways (CMPS) shares, and learn how to actually buy shares in a few easy steps. The 6 analysts with 12-month price forecasts for COMPASS Pathways stock have an average target of 45. 6% down on its price a month ago ($10. 00. " Still, Compass Pathways stock sank 16% in the stock market today Jul 28, 2023 · For Compass Pathways, (CMPS 1. Nov 13, 2021 · A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. 6 days ago · COMPASS Pathways (CMPS) (Real Time Quote from BATS) $7. Director. It operates through its subsidiaries which provide mental health care services. exchange. As a psychedelic therapy developer, Compass Pathways ( CMPS 1. Enter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 33 Mar 1, 2024 · Patrick Trucchio, an analyst from H. The 10 stocks that May 13, 2023 · Maxim Group analyst Jason McCarthy maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) yesterday and set a price target of $30. Full Ratings. The peak of this move, reaching $12. The average price target represents 501. Price as of May 10, 2024, 4:00 p. The associated price target is May 21, 2024 · Current Price. BE) stock quote, history, news and other vital information to help you with your stock trading and investing. Jason McCarthy’s rating is based on the Nov 18, 2020 · Compass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. Compass Pathways reported earnings per share of -55 cents. Zacks Rank: 3-Hold 3. Stock information. Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights. Style Scores: F Value | C Growth | B Nov 11, 2021 · Compass' shares are currently down by close to 30% so far this year. Aug 4, 2022 · Cash position at 30 June 2022 of $207. Nov 9, 2021 · Compass Pathways Stock Falls. Buy. 94 in the stock market today . 1899. The average COMPASS Pathways price target is $78, implying a 1,004. As of 12:22PM CEST. 85. What is COMPASS pathways plc stock price? On 2024-03-06, COMPASS pathways plc (CMPS-Q) stock closed at a price of Nov 21, 2021 · While both Compass Pathways ( CMPS 3. The increase Nov 3, 2023 · COMPASS Pathways (CMPS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Compass Pathways Wave Analysis: Huge Moves ahead Compass Pathways appears to have completed an impulsive 5-wave move to the upside, signaling significant strength in its recent price action. Share your opinion and gain insight from other stock traders and investors. 80M – a growth of 163. 02%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ. $9. Oct 22, 2021 · And the biotechnology industry's average price-to-sales multiple is 4. Stay ahead with Nov 30, 2020 · Current Price. 81 million in debt, giving a net cash position of $230. +0. 263. 83, with a low estimate of 16 and a high estimate of 120. 7. Compass Pathways PLC (5Y6. Retirement 101 Compass Pathways (NASDAQ:CMPS) $566 million Developing one psilocybin therapy, COMP360 Learn how to buy Compass Pathways PLC Stock with our step-by-step guide. 13% this week following yesterday's rise. However, the company has seen a fall of -10. This compares with $220. Its current price of $9. 18. 2 million at December 31, 2023. 212 per share for the current fiscal year. The drugmaker's stock is also trading at a 43% discount, relative to its 52-week high, at the moment. 60% Increase from the current price of $7. Compass stock has not recovered any of its lost value - the company Jun 28, 2021 · Compass on track to report data in late 2021. Currency in EUR. Top Stocks to Buy in 2024 Stock Market News Retirement Getting Started. 00 3,947 Compass Pathways Plc (CMPS) is a publicly traded medical care facilities business based in the US. 35%) (As of 05/15/2024 ET) Compare. Atai Life Sciences, a company that backs Compass Pathways ( CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the See the company profile for COMPASS Pathways plc (CMPS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and About an hour ago. 83% loss for the last 2 weeks. 06. 32 USD. 47M. Discover how to open a brokerage account, analyze stock performance, and place trades. Good Buy or Goodbye. 79%) are biopharma companies, their positioning couldn't be more different. 01% from a day low at $7. 71 to a high of $8. 39%) sank by nearly 30% through Thursday's closing bell this week, according to data from S&P Global Market Intelligence We would like to show you a description here but the site won’t allow us. The associated Oct 5, 2021 · Compass Pathways Plc. 10 compared to its previous closing price of 9. They see its shares rising by 307% compared to where it is The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Compass Pathways Plc wasn’t one of them. 4 billion at the moment isn't terribly high for a LONDON, Feb. While the IPO's price was set at $17, on the first day of trading, it opened at $23. May 16, 2024 · Discover real-time COMPASS Pathways Plc American Depository Shares (CMPS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. CMPS has been trading bullishly recently. The shares were sold at an average price of $10. COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head Find the latest COMPASS Pathways plc (CMPS) stock quote, history, news and other vital information to help you with your stock trading and investing. Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. Is COMPASS pathways plc worth watching? In the last year, there was no coverage of COMPASS pathways plc published on Stockchase. on Monday, May 13, 2024. 96%) have soared Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 60. 75, is notably identified as the B wave within an extended flat correction, potentially forming part of a larger 5-wave pa May 15, 2024 · COMPASS Pathways (CMPS) Stock Chart & Stock Price History. 9% to close at 35. $7. 9 million at March 31, 2024. View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company Compass Pathways Plc is an investment holding company. Stock quote & chart. COMPASS Pathways plc is a United Kingdom-based mental healthcare company. Discover historical prices for CMPS stock on Yahoo Finance. Nov 23, 2020 · 06:48 PM ET 11/23/2020. In the following year, 0 experts forecast that COMPASS Pathways's EBITDA will decrease by 27. Analysts expect adjusted earnings to reach $-2. 88. Presentations. The company’s shares closed yesterday at $8. Ritu Baral, an analyst who covers Compass Pathways stock, said the results were "extremely positive. During the day the price has varied from a low of $7. Total Debt. zk ai lv ea rp mk ha qh gj sn